SCHEMBL13638504

SCHEMBL13638504

C=C1CC(Nc2nccc(-c3ccc(C(=O)N[C@@H](Cc4ccccc4)C(=O)OC)s3)n2)CC(C)(C)N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 14/20 0.48
HPGDS O60760 2/20 0.40
MET P08581 1/20 0.37
KIT P10721 1/20 0.37
PRKCA P17252 1/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
MAPK3 P27361 1/20 0.37
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
CAMK2A Q9UQM7 1/20 0.37
TACR3 P29371 1/20 0.37
TEC P42680 1/20 0.37
TXK P42681 1/20 0.37
BTK Q06187 1/20 0.37
ITK Q08881 1/20 0.37
PSMB11 A5LHX3 1/20 0.37
PSMA7 O14818 1/20 0.37
PSMB1 P20618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638565 1.00 AKT3 (0.48) AKT3HPGDSMETKITPRKCA
SCHEMBL13638465 0.93 HPGDS (0.47) AKT3HPGDSMETKITPRKCA
SCHEMBL4479119 0.90 AKT3 (0.51) AKT3HPGDSMETKITPRKCA
SCHEMBL3470704 0.90 AKT3 (0.51) AKT3HPGDSMETKITPRKCA
SCHEMBL3470709 0.90 AKT3 (0.51) AKT3HPGDSMETKITPRKCA
SCHEMBL13638571 0.88 AKT3 (0.40) AKT3METKITPRKCAPRKACA
SCHEMBL13638474 0.85 AKT3 (0.50) AKT3TECTXKBTKITK
SCHEMBL13638466 0.84 AKT3 (0.62) AKT3TECTXKBTKITK
SCHEMBL16192862 0.83 AKT3 (0.47) AKT3HPGDSMETKITPRKCA
SCHEMBL16192776 0.83 AKT3 (0.47) AKT3HPGDSMETKITPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed